SOMERSET, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leading provider of healthcare technology solutions for medical practices and health systems nationwide, announces the participation of its medSR division at the Becker’s Annual Conference. The event will be held at the Hyatt Regency in Chicago from April 8th to the 11th, 2024.
The Becker’s Annual Conference serves as a platform for healthcare professionals to exchange insights into the evolving healthcare landscape. Attendees can expect discussions on emerging trends and connections that drive progress in the healthcare sector.
CareCloud's medSR division, featured at booth 215, will showcase its range of healthcare IT consulting and implementation services, including project management, subject matter experts (SMEs), IT staffing solutions, interim leadership support, training programs, and activation services. medSR's professionals leverage their platform expertise and operational strategies to meet client expectations efficiently.
Dwight Garvin, medSR's Executive Vice President and Chief Operations Officer, emphasized the importance of staying at the forefront of technological advancements in healthcare. He stressed the need for healthcare institutions to stay updated to deliver superior patient care. “Through collaboration with medSR, healthcare systems can access consultation services to optimize operations, refine revenue cycle management, and devise IT strategies,” he said. “This approach empowers healthcare systems to lower costs and elevate patient care.”
Attendees visiting booth 215 will have the opportunity to engage with medSR's professionals, who deliver customized solutions tailored to each organization's needs. Whether it involves streamlining workflows, implementing software solutions, or enhancing operational frameworks, medSR aims to deliver measurable outcomes and operational excellence.
For further information or to schedule a demo, please visit www.carecloud.com.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
About medSR
A division of CareCloud, medSR is a leading provider of comprehensive IT and operational services. Their portfolio includes EHR implementation, training, activation, optimization and support, as well as a wide range of revenue cycle consulting and managed services. With a dedicated and diverse team, medSR offers invaluable guidance to academic institutions, health systems, community hospitals, and medical practices throughout their entire technology transformation journey. From system selection and end-user training to revenue cycle optimization and beyond, medSR is committed to delivering exceptional solutions.
Follow medSR on LinkedIn.
Investor Contact:
Bill Korn
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.64 |
Daily Change: | -0.22 -5.70 |
Daily Volume: | 144,718 |
Market Cap: | US$59.190M |
November 12, 2024 August 13, 2024 July 17, 2024 May 14, 2024 April 17, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB